930 Consulting Ltd

930 Consulting Ltd is a consultancy firm established in 2015 that provides specialized drug discovery and medicinal chemistry services. The company supports a diverse client base, including biotechnology firms, contract research organizations, academic research groups, and non-profit organizations. Its core offerings range from project-specific advice on hit triage, compound procurement, and lead optimization to strategic guidance on portfolio management and organizational infrastructure development. Founded and directed by Dr. Graham Wynne, a Fellow of the Royal Society of Chemistry with over 25 years of industry experience, the consultancy leverages expertise in taking projects from initial target selection through to the delivery of clinical candidates.

The firm assists clients in navigating the complex challenges associated with drug development by providing technical execution and strategic planning. By offering flexible support tailored to various discovery strategies and target classes, 930 Consulting helps its partners manage technical workflows and execute due diligence for licensing transactions. Its engagement with the global life sciences sector is built upon the director's extensive track record in the pharmaceutical and biotech industries, aiming to facilitate efficient progression of discovery projects and organizational growth for its clients.